[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity
Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.
Jeffrey Lawrence Schwartz, socio di Bain Capital Investors e amministratore/proprietario del 10% di Kestra Medical Technologies, ha acquisito 10.909 unità di azioni vincolate (RSU) il 04/09/2025. Ogni RSU si converte in una azione ordinaria e le RSU maturano il 04/09/2026 soggette al mantenimento del rapporto di lavoro. Dopo l'acquisizione comunicata, il signor Schwartz possiede beneficiariamente 10.909 azioni direttamente e 27.019.225 azioni indirettamente, queste ultime detenute da Bain Charger Holdings, L.P. e West Affum Holdings, L.P., con entità di Bain Capital che detengono interessi di controllo. Il signor Schwartz declina la proprietà beneficiaria eccetto nella misura del suo interesse pecuniario.
Jeffrey Lawrence Schwartz, socio de Bain Capital Investors y director/propietario del 10% de Kestra Medical Technologies, adquirió 10.909 unidades de acciones restringidas (RSU) el 04/09/2025. Cada RSU se convierte en una acción ordinaria y las RSU se consolidan el 04/09/2026 sujetas a la continuación del servicio. Tras la adquisición comunicada, el Sr. Schwartz posee beneficiariamente 10.909 acciones de forma directa y 27.019.225 acciones de forma indirecta, estas últimas en poder de Bain Charger Holdings, L.P. y West Affum Holdings, L.P., con entidades de Bain Capital que mantienen intereses de control. El Sr. Schwartz renuncia a la propiedad beneficiaria salvo en la medida de su interés pecuniario.
Jeffrey Lawrence Schwartz는 Bain Capital Investors의 파트너이자 Kestra Medical Technologies의 이사/10% 소유자로서 2025년 9월 4일 10,909개의 제한부 주식 단위(RSU)를 취득했습니다. 각 RSU는 보통주 1주로 전환되며, RSU는 계속 근무를 조건으로 2026년 9월 4일에 보유권이 확정됩니다. 보고된 취득 이후 Schwartz 씨는 직접적으로 10,909주 및 간접적으로 27,019,225주를 실질적으로 보유하고 있으며, 간접 보유분은 Bain Charger Holdings, L.P.와 West Affum Holdings, L.P.가 보유하고 있고 Bain Capital 계열사가 지배적 지분을 보유하고 있습니다. Schwartz 씨는 자신의 금전적 이익이 미치는 범위를 제외하고는 실질적 소유권을 부인합니다.
Jeffrey Lawrence Schwartz, associé chez Bain Capital Investors et administrateur/propriétaire à hauteur de 10% de Kestra Medical Technologies, a acquis le 04/09/2025 10 909 unités d'actions restreintes (RSU). Chaque RSU se convertit en une action ordinaire et les RSU deviendront acquises le 04/09/2026 sous réserve de la poursuite du service. Après l'acquisition signalée, M. Schwartz détient bénéficiairement 10 909 actions directement et 27 019 225 actions indirectement, ces dernières détenues par Bain Charger Holdings, L.P. et West Affum Holdings, L.P., les entités de Bain Capital détenant les intérêts de contrôle. M. Schwartz décline toute propriété bénéficiaire sauf dans la mesure de son intérêt pécuniaire.
Jeffrey Lawrence Schwartz, Partner bei Bain Capital Investors und Direktor/10%-Eigentümer von Kestra Medical Technologies, erwarb am 04.09.2025 10.909 Restricted Stock Units (RSUs). Jede RSU wandelt sich in eine Stammaktie um und die RSUs werden am 04.09.2026 unter der Bedingung fortgesetzter Tätigkeit fällig. Nach der gemeldeten Erwerbung besitzt Herr Schwartz wirtschaftlich 10.909 Aktien direkt und 27.019.225 Aktien indirekt, letztere gehalten von Bain Charger Holdings, L.P. und West Affum Holdings, L.P., wobei Bain Capital-Gesellschaften Mehrheitsinteressen innehaben. Herr Schwartz weist eine wirtschaftliche Eigentümerschaft ab, außer insoweit sein pecuniäres Interesse betroffen ist.
- Director alignment: Time-vesting RSUs align the reporting persons incentives with long-term shareholder value.
- Full disclosure: The filing discloses indirect holdings and the ownership structure through Bain-affiliated entities.
- Concentration of control: A large block of 27,019,225 indirect shares is held by Bain-affiliated vehicles, indicating concentrated influence which may concern some investors.
Insights
TL;DR: Routine insider equity grant; signals alignment but minimal immediate market impact given large existing indirect holdings.
The reported grant of 10,909 RSUs is a standard long-term compensation vehicle tying executive incentives to equity performance. Vesting is time-based one year out, which supports retention. The incremental economic stake is small relative to the reported 27,019,225 indirect shares tied to Bain-affiliated vehicles, so the marginal effect on control or market float is negligible. For investors, this demonstrates continued alignment of the director with shareholder outcomes but does not represent a material change in ownership or control.
TL;DR: Governance-wise this is a customary director grant; disclosure clarifies indirect ownership through Bain entities.
The Form 4 properly discloses both the time-vesting RSUs and the web of indirect holdings through Bain Charger and West Affum, preserving transparency about potential shared voting/dispositive power. The filing includes the required disclaimer of beneficial ownership except for pecuniary interest, which is standard when ownership is held in affiliated partnerships. No unusual derivative or disposition activity is reported, indicating no immediate governance changes.
Jeffrey Lawrence Schwartz, socio di Bain Capital Investors e amministratore/proprietario del 10% di Kestra Medical Technologies, ha acquisito 10.909 unità di azioni vincolate (RSU) il 04/09/2025. Ogni RSU si converte in una azione ordinaria e le RSU maturano il 04/09/2026 soggette al mantenimento del rapporto di lavoro. Dopo l'acquisizione comunicata, il signor Schwartz possiede beneficiariamente 10.909 azioni direttamente e 27.019.225 azioni indirettamente, queste ultime detenute da Bain Charger Holdings, L.P. e West Affum Holdings, L.P., con entità di Bain Capital che detengono interessi di controllo. Il signor Schwartz declina la proprietà beneficiaria eccetto nella misura del suo interesse pecuniario.
Jeffrey Lawrence Schwartz, socio de Bain Capital Investors y director/propietario del 10% de Kestra Medical Technologies, adquirió 10.909 unidades de acciones restringidas (RSU) el 04/09/2025. Cada RSU se convierte en una acción ordinaria y las RSU se consolidan el 04/09/2026 sujetas a la continuación del servicio. Tras la adquisición comunicada, el Sr. Schwartz posee beneficiariamente 10.909 acciones de forma directa y 27.019.225 acciones de forma indirecta, estas últimas en poder de Bain Charger Holdings, L.P. y West Affum Holdings, L.P., con entidades de Bain Capital que mantienen intereses de control. El Sr. Schwartz renuncia a la propiedad beneficiaria salvo en la medida de su interés pecuniario.
Jeffrey Lawrence Schwartz는 Bain Capital Investors의 파트너이자 Kestra Medical Technologies의 이사/10% 소유자로서 2025년 9월 4일 10,909개의 제한부 주식 단위(RSU)를 취득했습니다. 각 RSU는 보통주 1주로 전환되며, RSU는 계속 근무를 조건으로 2026년 9월 4일에 보유권이 확정됩니다. 보고된 취득 이후 Schwartz 씨는 직접적으로 10,909주 및 간접적으로 27,019,225주를 실질적으로 보유하고 있으며, 간접 보유분은 Bain Charger Holdings, L.P.와 West Affum Holdings, L.P.가 보유하고 있고 Bain Capital 계열사가 지배적 지분을 보유하고 있습니다. Schwartz 씨는 자신의 금전적 이익이 미치는 범위를 제외하고는 실질적 소유권을 부인합니다.
Jeffrey Lawrence Schwartz, associé chez Bain Capital Investors et administrateur/propriétaire à hauteur de 10% de Kestra Medical Technologies, a acquis le 04/09/2025 10 909 unités d'actions restreintes (RSU). Chaque RSU se convertit en une action ordinaire et les RSU deviendront acquises le 04/09/2026 sous réserve de la poursuite du service. Après l'acquisition signalée, M. Schwartz détient bénéficiairement 10 909 actions directement et 27 019 225 actions indirectement, ces dernières détenues par Bain Charger Holdings, L.P. et West Affum Holdings, L.P., les entités de Bain Capital détenant les intérêts de contrôle. M. Schwartz décline toute propriété bénéficiaire sauf dans la mesure de son intérêt pécuniaire.
Jeffrey Lawrence Schwartz, Partner bei Bain Capital Investors und Direktor/10%-Eigentümer von Kestra Medical Technologies, erwarb am 04.09.2025 10.909 Restricted Stock Units (RSUs). Jede RSU wandelt sich in eine Stammaktie um und die RSUs werden am 04.09.2026 unter der Bedingung fortgesetzter Tätigkeit fällig. Nach der gemeldeten Erwerbung besitzt Herr Schwartz wirtschaftlich 10.909 Aktien direkt und 27.019.225 Aktien indirekt, letztere gehalten von Bain Charger Holdings, L.P. und West Affum Holdings, L.P., wobei Bain Capital-Gesellschaften Mehrheitsinteressen innehaben. Herr Schwartz weist eine wirtschaftliche Eigentümerschaft ab, außer insoweit sein pecuniäres Interesse betroffen ist.